Am J Ophthalmol

1. KIM TY, Choi EY, Lee S, Choi YJ, et al
   Clinical Utility of Ultra-Widefield Swept-Source OCT for Intraocular Tumors: Comparison With Ultrasonography, SD-OCT, and MRI.
   Am J Ophthalmol. 2026 Jun 30:S0002-9394(26)00355.
   

   >> Share

   
   

   
   Ann Surg Oncol

2. VAN DOREN AS, Shah H, Chen R, Shah D, et al
   The Impact of Initial Biopsy Modality and Provider Credentials on Upstaging and Management Changes in Cutaneous Melanoma.
   Ann Surg Oncol. 2026 Sep 1. doi: 10.1245/s10434-026-20386.
   

   >> Share

   
   

   
   Anticancer Res

3. MARCHESE PV, Zannini I, DE Biase D, Corti B, et al
   Exploring the Role of TERT Promoter Mutations in Advanced Melanoma Treated With BRAF/MEK Inhibitors or Immune Checkpoint Inhibitors.
   Anticancer Res. 2026;46:5013-5029.
   

   >> Share

   
   
4. BROCK LF, Demirors B, Godbole N, Bowers JC, et al
   Regional Disparities in Socioeconomic Factors and Advanced-stage Presentation in Melanoma: A National Cancer Database Analysis (2004-2020).
   Anticancer Res. 2026;46:4985-4991.
   

   >> Share

   
   
5. POPP R, Elston D
   Circadian Rhythm Disruption and Cutaneous Carcinogenesis.
   Anticancer Res. 2026;46:4791-4796.
   

   >> Share

   
   
6. CHO H, Zheng Z, Zhang M, Seo J, et al
   Mechanical Stress as a Pathomechanism of Plantar Acral Melanoma.
   Anticancer Res. 2026;46:4813-4826.
   

   >> Share

   
   

   
   J Am Acad Dermatol

7. JAMES NRJ, Taylor MA, Young Yu GS, Padron F, et al
   Disparities in Time to Treatment of Acral Lentiginous Melanoma: A Retrospective Cohort Analysis of the Surveillance, Epidemiology, and End Results Database.
   J Am Acad Dermatol. 2026 Sep 3:S0190-9622(26)03442.
   

   >> Share

   
   

   
   Melanoma Res

8. DING W, Ci C, Yuan T, Wei H, et al
   DPM2 promotes melanoma progression and serves as a prognostic factor.
   Melanoma Res. 2026 Sep 3. doi: 10.1097/CMR.0000000000001132.
   

   >> Share

   
   
9. MOUFARREJ A, Biermann S, Springer R, Hoff NP, et al
   Targeted BRAF /MEK inhibition as a salvage therapy for patients with metastatic melanoma harboring a BRAF L597R mutation: two case reports and review of the literature.
   Melanoma Res. 2026 Aug 31. doi: 10.1097/CMR.0000000000001135.
   

   >> Share

   
   

Free Medical Abstracts
Privacy Policy
Sponsors
Share